Here, we first assessed the abnormal expression of GIV through pan-cancer analysis and found the expression of GIV has also been confirmed in several tumors, which is consistent with previous reports.[28] We also established that the expression of GIV in LIHC patients was higher than in nonmalignant tissues and that it is differentially expressed at various LIHC stages. The gene discussed is CCDC88A; the disease is cancer.